Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20447644 | 0.82 | ALDH1A1 (0.36) | CHRM3ALDH1A1CYP1A2KEAP1NFE2L2 | |
| SCHEMBL600028 | 0.73 | MAPK1 (0.32) | CHRM3ALDH1A1CYP1A2ALOX15CHRM2 | |
| SCHEMBL17042075 | 0.72 | HRH1 (0.43) | — | |
| SCHEMBL328752 | 0.70 | HSD11B1 (0.31) | ALDH1A1CYP1A2 | |
| SCHEMBL14321417 | 0.67 | CYP3A4 (0.38) | — | |
| SCHEMBL354893 | 0.66 | CHRM3 (0.34) | CHRM3ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL353649 | 0.66 | LMNA (0.32) | CHRM3 | |
| SCHEMBL9309557 | 0.66 | — | — | |
| SCHEMBL15520559 | 0.65 | CRBN (0.34) | CYP1A2ATM | |
| SCHEMBL5024251 | 0.65 | NOS1 (0.33) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601671-B1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7148246-B2 | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1601671-A1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20040198786-A1 | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| WO-2004076447-A1 | CYCLOALKYL DERIVATIVES COMPRISING BIOISOSTERIC CARBOXYLIC ACID GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198786-A1 | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals | GPR119, CPT1A, PC | CHRM3 2415/4885CNR2 302/4885ALDH1A1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.